Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-like peptide-1

Table 1 Patient characteristics (n = 76)

	Active GLP-1 low (n = 26)	Active GLP-1 mid (n = 25)	Active GLP-1 high (n = 25)	P value
Sex male/female (%)	82	88	88
Age (yr)	60.5 ± 13.7	63.8 ± 10.8	58.5 ± 15.3
Disease duration (yr)	16.2 ± 11.2	15.5 ± 10.8	12.7 ± 10.4
FPG (mg/dL)	161.1 ± 35.4	160.1 ± 41.6	160.7 ± 45.3
HbA1c (%)	7.43 ± 1.18	7.44 ± 0.66	7.61 ± 1.32
BMI (kg/m2)	22.3 ± 5.8	24.1 ± 10.7	26.8 ± 5.6	1
Sulfonylurea (%)	54	52	57
Biguanide (%)	45	52	76
Systolic BP (mmHg)	126.8 ± 17.5	133.9 ± 15.1	129.2 ± 17.8
Diastolic BP (mmHg)	74.5 ± 10.8	76.8 ± 13.6	78.0 ± 12.2
Proteinuria	8	22	21
γGTP (IU/L)	38.5 ± 34.3	45.9 ± 35.5	43.3 ± 27.5
AST (IU/L)	28.3 ± 34.0	22.9 ± 8.2	25.0 ± 10.0
ALT (IU/L)	36.0 ± 60.1	23.9 ± 15.8	32.2 ± 21.3
TC (mg/dL)	193.3 ± 29.6	214.3 ± 32.0	189.1 ± 26.0
HDLC (mg/dL)	57.0 ± 16.9	61.6 ± 16.0	51.9 ± 14.3
TG (mg/dL)	127.1 ± 66.3	133.4 ± 132.0	135.1 ± 68.5
LDLC (mg/dL)	109.8 ± 26.9	122.4 ± 36.5	110.0 ± 24.5
UA (mg/dL)	4.87 ± 0.98	5.22 ± 1.09	5.65 ± 1.27	1
Cr (mg/dL)	0.83 ± 0.23	0.77 ± 0.15	0.75 ± 0.16
eGFR (mL/min)	76.7 ± 21.3	78.8 ± 17.7	83.1 ± 19.3

Data is presented as mean ± SD, or %.

¹Mean statistical significance P < 0.05. GLP-1: Glucagon-like peptide-1; HbA1c: Hemoglobin A1c; eGFR: Epidermal growth factor receptor; FPG: Fasting plasma glucose; BMI: Body mass index; GTP: Guanosine triphosphate; HDLC: High density lipoprotein cholesterol; LDLC: Low density lipoprotein cholesterol; AST: Glutamic-oxalacetic transaminase; ALT: Alanine aminotransferase; TG: Thyroglobulin; Cr: Chromium.